Allergan builds obesity treatment portfolio
This article was originally published in The Gray Sheet
Executive Summary
Allergan will pursue FDA approval of EndoArt's EasyBand remote-controlled gastric banding system for treatment of morbid obesity after acquiring the Swiss company for $97 million, the firm announces Feb. 22. The "next-generation" implant, intended for placement around the upper stomach, allows telemetric adjustment via an external controller to fit each patient's individual weight loss needs, the company says. Approved in Europe in mid-2006, EasyBand complements Allergan's Lap-Band adjustable gastric banding system. Allergan gained Lap-Band - currently the only adjustable implant for individualized weight loss approved in the United States - in its $3.2 billion purchase of Inamed last year (1"The Gray Sheet" April 3, 2006, p. 6). Allergan also offers its nonsurgical BIB BioEnterics intragastric balloon for obesity treatment outside the United States...
You may also be interested in...
Allergan Details Revenue Expectations From Newly Acquired Inamed
Allergan expects its recently completed acquisition of Inamed to add $355 mil. to $395 mil. in sales revenue this year
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.
Adalvo Hails First European Launch Of Prolonged-Release Pregabalin
After the drug’s approval for use in neuropathic pain within the EU last December, Adalvo announced the analgesic’s first European launch in Germany.